SCHEMBL20119767

SCHEMBL20119767

Fc1nc(NCc2nccs2)c2cc[nH]c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 1/20 0.40
▸ TRPM5 Q9NZQ8 1/20 0.39
▸ CLK2 P49760 2/20 0.36
▸ CLK4 Q9HAZ1 2/20 0.36
▸ PTGS2 P35354 1/20 0.36
▸ CLK1 P49759 1/20 0.36
▸ CLK3 P49761 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ DYRK1B Q9Y463 1/20 0.36
▸ JAK2 O60674 2/20 0.36
▸ JAK1 P23458 1/20 0.36
▸ TYK2 P29597 1/20 0.36
▸ JAK3 P52333 1/20 0.36
▸ TLR7 Q9NYK1 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ KDM1A O60341 1/20 0.35
▸ MAOB P27338 1/20 0.35
▸ AURKB Q96GD4 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.34
▸ DRD4 P21917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119691 0.86 HRH4 (0.43) HRH4TRPM5CLK2CLK4CLK1
SCHEMBL20119839 0.77 TRPM5 (0.42) HRH4TRPM5CLK2CLK4PTGS2
SCHEMBL20119853 0.77 JAK2 (0.46) CLK2CLK4PTGS2JAK2JAK1
SCHEMBL2461578 0.70 JAK2 (0.53) HRH4JAK2
SCHEMBL20119563 0.67 HRH4 (0.36) HRH4TRPM5CLK2CLK4PTGS2
SCHEMBL30297953 0.67 CYP2C19 (0.36) HRH4DYRK1AJAK2JAK1TYK2
SCHEMBL18797683 0.66 HRH4 (0.44) HRH4TRPM5CLK2CLK4CLK1
Hydrochloric Acid SCHEMBL30297969 0.66 CYP2C19 (0.36) HRH4DYRK1AJAK2JAK1TYK2
SCHEMBL17933819 0.65 PLK4 (0.41) HRH4TRPM5CLK2CLK4CLK1
SCHEMBL20119849 0.65 PDE5A (0.35) CLK2CLK4AURKBHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 — — US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 — — US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 — — US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 — — US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 — — US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 — — US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885TRPM5 4390/4885CLK2 3638/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885TRPM5 4390/4885CLK2 3638/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885TRPM5 4390/4885CLK2 3638/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885TRPM5 4390/4885CLK2 3638/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HRH4 4263/4885TRPM5 4390/4885CLK2 3638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback